Journal
FUTURE MEDICINAL CHEMISTRY
Volume 10, Issue 9, Pages 1113-1130Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc-2017-0203
Keywords
anticancer treatment; combination therapy; epigenetic agents
Categories
Funding
- Ministry of Education, Youth and Sports of the Czech Republic within the National Sustainability Programme II (Project BIOCEV-FAR) [LQ1604]
- projects 'BIO-CEV' [CZ.1.05/1.1.00/02.0109, LO1304, LH 14008]
- Charles University in Prague [UNCE 204064, Progress Q26/LF1, Progress Q27/LF1]
- MZCR [RVO-VFN64165/2012]
- Ministry of Agriculture of the Czech Republic [QJ1610515]
- Ministry of Industry and Trade of the Czech Republic [FV20572]
- Grant Agency of the Czech Republic [GACR 17-07822S]
Ask authors/readers for more resources
In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available